Predictors of delayed therapy after expectant management for localized prostate cancer in the era of prostate-specific antigen

Oncology

Volumn 67, Issue 3-4, 2004, Pages 194-202

  Panagiotou, Irene ^a   Beer, Tomasz M ^a   Hsieh, Yi Ching ^a   Mori, Motomi ^a   Peters, Laura ^b   Klein, Thomas ^b   Garzotto, Mark ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

Androgen deprivation; Expectant management; Prostate cancer; Treatment

Indexed keywords

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; BEAM THERAPY; BRACHYTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; FOLLOW UP; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; RISK FACTOR; TRANSRECTAL ULTRASONOGRAPHY; TUMOR BIOPSY;

ADENOCARCINOMA; ANALYSIS OF VARIANCE; COHORT STUDIES; HUMANS; MALE; NEOPLASM STAGING; OBSERVATION; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 9244244291     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081317     Document Type: Article

References (24)

1. Wilt TJ, Brawer MK: The Prostate Cancer Intervention Versus Observation Trial (PIVOT). Oncology (Huntingt) 1997;11:1133-1139.
2. Johansson JE, Holmberg L, Johansson S, Bergstrom R, Adami HO: Fifteen-year survival in prostate cancer. A prospective, populationbased study in Sweden. JAMA 1997;277:467-471.
3. Adolfsson J, Steineck G, Hedlund PO: Deferred treatment of clinically localized low-grade prostate cancer: Actual 10-year and projected 15-year follow-up of the Karolinska series. Urology 1997;50:722-726.
4. Albertsen PC, Hanley JA, Gleason DF, Barry MJ: Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998;280:975-980.
5. Chodak GW, Thisted RA, Gerber GS, Johansson JE, Adolfsson J, Jones GW, Chisholm GD, Moskovitz B, Livne PM, Warner J: Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994;330:242-248.
6. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J: Long-term survival among men with conservatively treated localized prostate cancer. JAMA 1995;274:626-631.
7. Borre M, Nerstrom B, Overgaard J: The natural history of prostate carcinoma based on a Danish population treated with no intent to cure. Cancer 1997;80:917-928.
8. Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Haggman M, Andersson SO, Spangberg A, Busch C, Nordling S, Palmgren J, Adami HO, Johansson JE, Norlen BJ: A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002;347:781-789.
9. Stephenson RA: Prostate cancer trends in the era of prostate-specific antigen. An update of incidence, mortality, and clinical factors from the SEER database. Urol Clin North Am 2002;29:173-181.
10. McLaren DB, McKenzie M, Duncan G, Pickles T: Watchful waiting or watchful progression? Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma. Cancer 1998;82:342-348.
11. Koppie TM, Grossfeld GD, Miller D, Yu J, Stier D, Broering JM, Lubeck D, Henning JM, Flanders SC, Carroll PR: Patterns of treatment of patients with prostate cancer initially managed with surveillance: Results from the CaPSURE database. Cancer of the Prostate Strategic Urological Research Endeavor. J Urol 2000;164:81-88.
12. Zietman AL, Thakral H, Wilson L, Schellhammer P: Conservative management of prostate cancer in the prostate specific antigen era: The incidence and time course of subsequent therapy. J Urol 2001;166:1702-1706.
13. Choo R, Klotz L, Danjoux C, Morton GC, DeBoer G, Szumacher E, Fleshner N, Bunting P, Hruby G: Feasibility study: Watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 2002;167:1664-1669.
14. D'Amico AV, Whittington R, Malkowicz SB, Fondurulia J, Chen MH, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw AA, Wein A, Coleman CN: Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 1999;17:168-172.
15. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-1597.
16. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT: A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90:766-771.
17. Terris MK, Stamey TA: Determination of prostate volume by transrectal ultrasound. J Urol 1991;145:984-987.
18. Benson MC, Whang IS, Pantuck A, Ring K, Kaplan SA, Olsson CA, Cooner WH: Prostate specific antigen density: A means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992;147:815-816.
19. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, Fozard JL, Walsh PC: Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992;267:2215-2220.
20. Egawa S, Matsumoto K, Suyama K, Iwamura M, Kuwao S, Baba S: Observations of prostate specific antigen doubling time in Japanese patients with nonmetastatic prostate carcinoma. Cancer 1999;86:463-469.
21. Gerber GS, Gornik HL, Goldfischer ER, Chodak GW, Rukstalis DB: Evaluation of changes in prostate specific antigen in clinically localized prostate cancer managed without initial therapy. J Urol 1998;159:1243-1246.
22. Pearson JD, Carter HB: Natural history of changes in prostate specific antigen in early stage prostate cancer. J Urol 1994;152:1743-1748.
23. Schmid HP, McNeal JE, Stamey TA: Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 1993;71:2031-2040.
24. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Silver B, Henry L, Hurwitz M, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw AA, Wein A, Richie JP: Clinical utility of percent-positive prostate biopsies in predicting biochemical outcome after radical prostatectomy or external-beam radiation therapy for patients with clinically localized prostate cancer. Mol Urol 2000;4:171-175.